Advertisement

Journal of Neurology

, Volume 234, Issue 5, pp 363–363 | Cite as

High-dose intravenous gamma-globulin therapy for myasthenia gravis

  • I. Bonaventura Ibars
  • J. Ponseti
  • T. Español
  • J. Matias-Guiu
  • A. Codina-Puiggros
Letters To The Editors

Keywords

Public Health 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Devathasan G, Kueh YK, Chong PN (1984) High-dose intravenous gammaglobulin for myasthenia gravis. Lancet II:809–810Google Scholar
  2. 2.
    Fateh-Moghadam A, Wick M, Besinger V, Gemsen RG (1984) High-dose intravenous gammaglobulin for myasthenia gravis. Lancet I:848–849Google Scholar
  3. 3.
    Gajdos P, Outin H, Elkharrat D, Brunel D, Rohan-Chabot P, Raphael JC, Goulon M, Goulon-Goeau C, Morel E (1984) High-dose intravenous gammaglobulin for myasthenia gravis. Lancet I:406–407Google Scholar
  4. 4.
    Ippoliti G, Cosi V, Piccolo G, Lombardi M, Mantegaz R (1984) High-dose intravenous gammaglobulin for myasthenia gravis. Lancet II:809Google Scholar
  5. 5.
    Mossman S, Vincent A, Newsom-Davis J (1986) Myasthenia gravis without acetylcholine-receptor antibody: a distinct disease entity. Lancet I:116–118Google Scholar

Copyright information

© Springer-Verlag 1987

Authors and Affiliations

  • I. Bonaventura Ibars
    • 1
  • J. Ponseti
    • 2
  • T. Español
    • 3
  • J. Matias-Guiu
    • 1
  • A. Codina-Puiggros
    • 1
  1. 1.Neurology Service, Hospital del Valle de HebrónUniversidad Autónoma de BarcelonaSpain
  2. 2.Department of Surgery, Hospital del Valle de HebrónUniversidad Autónoma de BarcelonaSpain
  3. 3.Laboratory of Immunology, Hospital del Valle de HebrónUniversidad Autónoma de BarcelonaSpain

Personalised recommendations